The DOI matches its Crossref record; 63 of the 64 references it cites were found in a registry or an index.
A Novel Role for Histone Deacetylase 6 in the Regulation of the Tolerogenic STAT3/IL-10 Pathway in APCs
Open accessAbstract
APCs are critical in T cell activation and in the induction of T cell tolerance. Epigenetic modifications of specific genes in the APC play a key role in this process, and among them histone deacetylases (HDACs) have emerged as key participants. HDAC6, one of the members of this family of enzymes, has been shown to be involved in regulation of inflammatory and immune responses. In this study, to our knowledge we show for the first time that genetic or pharmacologic disruption of HDAC6 in macrophages and dendritic cells results in diminished production of the immunosuppressive cytokine IL-10 and induction of inflammatory APCs that effectively activate Ag-specific naive T cells and restore the responsiveness of anergic CD4+ T cells. Mechanistically, we have found that HDAC6 forms a previously unknown molecular complex with STAT3, association that was detected in both the cytoplasmic and nuclear compartments of the APC. By using HDAC6 recombinant mutants we identified the domain comprising amino acids 503–840 as being required for HDAC6 interaction with STAT3. Furthermore, by re–chromatin immunoprecipitation we confirmed that HDAC6 and STAT3 are both recruited to the same DNA sequence within the Il10 gene promoter. Of note, disruption of this complex by knocking down HDAC6 resulted in decreased STAT3 phosphorylation—but no changes in STAT3 acetylation—as well as diminished recruitment of STAT3 to the Il10 gene promoter region. The additional demonstration that a selective HDAC6 inhibitor disrupts this STAT3/IL-10 tolerogenic axis points to HDAC6 as a novel molecular target in APCs to overcome immune tolerance and tips the balance toward T cell immunity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“STAT3–HDAC6 transcriptionally upregulates IL-10, preventing effective Ag-specific CD4+ T cell activation in tumor-bearing mice”
From Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 To Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution (2020) · cites this paper as Cheng et al., 2014
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“use of a HDAC inhibitor enabled effective T cell priming and antitumor response”
From Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 To Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution (2020) · cites this paper as Cheng et al., 2014
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A new mathematical model for relative quantification in real-time RT-PCR
Pfaffl, M. W. (2001) · Nucleic Acids Research · doi:10.1093/nar/29.9.e45 · Cited by 34,610
The regulation of IL-10 production by immune cells
Saraiva, M., & O’Garra, A. (2010) · Nature reviews. Immunology · doi:10.1038/nri2711 · Cited by 3,293
Histone deacetylases (HDACs): characterization of the classical HDAC family
RUIJTER, A. J. M. D., GENNIP, A. H. V., CARON, H. N., KEMP, S., & KUILENBURG, A. B. P. V. (2003) · Biochemical Journal · doi:10.1042/bj20021321 · Cited by 3,114
Activation of p53 Sequence-Specific DNA Binding by Acetylation of the p53 C-Terminal Domain
Gu, W., & Roeder, R. G. (1997) · Cell · doi:10.1016/s0092-8674(00)80521-8 · Cited by 2,559
HDAC6 is a microtubule-associated deacetylase
Hubbert, C., Guardiola, A., Shao, R., Kawaguchi, Y., Ito, A., Nixon, A., Yoshida, M., Wang, X.-F., & Yao, T.-P. (2002) · Nature · doi:10.1038/417455a · Cited by 2,403
Nasir, O. (2013) · Kidney & Blood Pressure Research · doi:10.1159/000350152 · Cited by 2,331
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer
Minucci, S., & Pelicci, P. G. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1779 · Cited by 2,234
Gabrilovich, D. I., Chen, H. L., Girgis, K. R., Cunningham, H. T., Meny, G. M., Nadaf, S., Kavanaugh, D., & Carbone, D. P. (1996) · Nature Medicine · doi:10.1038/nm1096-1096 · Cited by 1,977
Regulatory T Cell-Derived Interleukin-10 Limits Inflammation at Environmental Interfaces
Rubtsov, Y. P., Rasmussen, J. P., Chi, E. Y., Fontenot, J., Castelli, L., Ye, X., Treuting, P., Siewe, L., Roers, A., Henderson, W. R., et al. (2008) · Immunity · doi:10.1016/j.immuni.2008.02.017 · Cited by 1,586
Acetylation and deacetylation of non-histone proteins
Glozak, M. A., Sengupta, N., Zhang, X., & Seto, E. (2005) · Gene · doi:10.1016/j.gene.2005.09.010 · Cited by 1,584
Self-citation
Cited by
Sorted by citations
Histone Deacetylase Inhibitors as Anticancer Drugs
Eckschlager, T., Plch, J., Stiborova, M., & Hrabeta, J. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071414 · Cited by 1,206
Pro- and anti-inflammatory effects of short chain fatty acids on immune and endothelial cells
Li, M., van Esch, B. C. A. M., Wagenaar, G. T. M., Garssen, J., Folkerts, G., & Henricks, P. A. J. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.05.003 · Cited by 650
Histone deacetylase 6 in cancer
Li, T., Zhang, C., Hassan, S., Liu, X., Song, F., Chen, K., Zhang, W., & Yang, J. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0654-9 · Cited by 337
The emerging role of epigenetics in human autoimmune disorders
Mazzone, R., Zwergel, C., Artico, M., Taurone, S., Ralli, M., Greco, A., & Mai, A. (2019) · Clinical Epigenetics · doi:10.1186/s13148-019-0632-2 · Cited by 318
Hull, E. E., Montgomery, M. R., & Leyva, K. J. (2016) · BioMed Research International · doi:10.1155/2016/8797206 · Cited by 319
Bharadwaj, U., Kasembeli, M. M., Robinson, P., & Tweardy, D. J. (2020) · Pharmacological Reviews · doi:10.1124/pr.119.018440 · Cited by 314
“, 2014), while using an HDACi, ↑effective T cell priming and antitumor response (Wang et al., 2011a; Cheng et al., 2014) Inhibition Preclinical”
BackgroundMethodInfluentialEssential role of HDAC6 in the regulation of PD‐L1 in melanoma
Lienlaf, M., Perez-Villarroel, P., Knox, T. J., Pabon, M. M., Sahakian, E., Powers, J. J., Woan, K. V., Lee, C., Cheng, F., Deng, S., et al. (2016) · Molecular Oncology · doi:10.1016/j.molonc.2015.12.012 · Cited by 171
Self-citationKnox, T., Sahakian, E., Banik, D., Hadley, M., Palmer, E., Noonepalle, S., Kim, J., Powers, J., Gracia-Hernandez, M., Oliveira, V., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-42237-3 · Cited by 170
Self-citationAdeegbe, D. O., Liu, Y., Lizotte, P. H., Kamihara, Y., Aref, A. R., Almonte, C. G., Dries, R., Li, Y., Liu, S., Wang, X., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1020 · Cited by 150
Woan, K. V., Lienlaf, M., Perez-Villarroel, P., Lee, C., Cheng, F., Knox, T. J., Woods, D. M., Barrios, K., Powers, J. J., Sahakian, E., et al. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.04.002 · Cited by 138
Self-citationImmunoepigenetics Combination Therapies: An Overview of the Role of HDACs in Cancer Immunotherapy
Banik, D., Moufarrij, S., & Villagra, A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20092241 · Cited by 137
Self-citationRegulatory dendritic cells in autoimmunity: A comprehensive review
Liu, J., & Cao, X. (2015) · Journal of Autoimmunity · doi:10.1016/j.jaut.2015.07.011 · Cited by 136
STAT3, a master regulator of anti-tumor immune response
Rébé, C., & Ghiringhelli, F. (2019) · Cancers · doi:10.3390/cancers11091280 · Cited by 129
de Groot, A. E., & Pienta, K. J. (2018) · Oncotarget · doi:10.18632/oncotarget.24556 · Cited by 124
Knox, T. J., Sahakian, E., Banik, D., Hadley, M. M., Palmer, E., Noonepalle, S. K. R., Kim, J. S., Powers, J. J., Gracia-Hernandez, M., Oliveira, V. A., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-51403-6 · Cited by 118
Self-citationMoufarrij, S., Srivastava, A., Gomez, S., Hadley, M. M., Palmer, E., Austin, P. T., Chisholm, S., Diab, N., Roche, K. C., Yu, A. Y. C., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-60409-4 · Cited by 119
Self-citationThe Emerging Role of Epigenetics in Autoimmune Thyroid Diseases
Wang, B., Shao, X., Song, R., Xu, D., & Zhang, J. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00396 · Cited by 100
Li, A., Chen, P., Leng, Y., & Kang, J. (2018) · Oncogene · doi:10.1038/s41388-018-0379-9 · Cited by 91
Gatla, H. R., Muniraj, N., Thevkar, P., Yavvari, S., Sukhavasi, S., & Makena, M. R. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20051110 · Cited by 91
Recent Update of HDAC Inhibitors in Lymphoma
Chen, I., Sethy, B., & Liou, J. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.576391 · Cited by 83
The therapeutic hope for HDAC6 inhibitors in malignancy and chronic disease
Batchu, S. N., Brijmohan, A. S., & Advani, A. (2016) · Clinical Science · doi:10.1042/cs20160084 · Cited by 86
HDAC6 selective inhibition of melanoma patient T-cells augments anti-tumor characteristics
Laino, A. S., Betts, B. C., Veerapathran, A., Dolgalev, I., Sarnaik, A. A., Quayle, S. N., Jones, S. S., Weber, J. S., & Woods, D. M. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0517-0 · Cited by 85
Self-citationWu, H., Cheng, X. W., Hu, L., Takeshita, K., Chen, H., Du, Q., Li, X., Zhu, E., Huang, Z., Yisireyili, M., et al. (2016) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.115.307110 · Cited by 81
Myeloid-derived suppressor cells (MDSC): When good intentions go awry
Sanchez‐Pino, M. D., Dean, M. J., & Ochoa, A. C. (2021) · Cellular Immunology · doi:10.1016/j.cellimm.2021.104302 · Cited by 72
Regulation of Retinoic Acid Inducible Gene-I (RIG-I) Activation by the Histone Deacetylase 6
Liu, H. M., Jiang, F., Loo, Y., Hsu, S., Hsiang, T.-Y., Marcotrigiano, J., & Gale, M. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.06.015 · Cited by 71
Tsimberidou, A. M., Beer, P. A., Cartwright, C., Haymaker, C., Vo, H. H., Kiany, S., Cecil, A., Dow, J., Haque, K., Silva, F. A., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0238 · Cited by 69
Ariel, O., Gendron, D., Dudemaine, P.-L., Gévry, N. Y., Ibeagha-Awemu, E. M., & Bissonnette, N. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02874 · Cited by 70
Banik, D., Noonepalle, S. K. R., Hadley, M. M., Palmer, E., Gracia-Hernandez, M., Delgado, C. Z., Manhas, N., Simonyan, H., Young, C. N., Popratiloff, A. S., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-3738 · Cited by 68
Self-citationUnexpected implications of STAT3 acetylation revealed by genetic encoding of acetyl-lysine
Belo, Y., Mielko, Z. E., Nudelman, H., Afek, A., Ben‐David, O., Shahar, A., Zarivach, R., Gordân, R., & Arbely, E. (2019) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2019.05.019 · Cited by 67
Targeted inhibition of histone deacetylase 6 in inflammatory diseases
Ran, J., & Zhou, J. (2019) · Thoracic Cancer · doi:10.1111/1759-7714.12974 · Cited by 63
Epigenetic and transcriptional mechanisms for the regulation of IL-10
Zhang, H., & Kuchroo, V. K. (2019) · Seminars in Immunology · doi:10.1016/j.smim.2019.101324 · Cited by 65
Noonepalle, S. K. R., Shen, S., Ptáček, J., Tavares, M. T., Zhang, G., Stránský, J., Pavlı́ček, J., Ferreira, G. M., Hadley, M. M., Pelaez, G. D., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00567 · Cited by 62
Self-citationAlseksek, R. K., Ramadan, W. S. H., Saleh, E., & El‐Awady, R. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158141 · Cited by 59
Epigenetic regulators of programmed death-ligand 1 expression in human cancers
Kumar, S., & Sharawat, S. K. (2018) · Translational research · doi:10.1016/j.trsl.2018.05.011 · Cited by 55
Role of the HDAC6/STAT3 pathway in regulating PD-L1 expression in osteosarcoma cell lines
Keremu, A., Aimaiti, A., Liang, Z., & Zou, X. (2018) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-018-3721-6 · Cited by 53
Targeting Macrophages as a Therapeutic Option in Coronavirus Disease 2019
Gracia-Hernandez, M., Sotomayor, E. M., & Villagra, A. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.577571 · Cited by 54
Self-citationModulation of Antitumor Immunity with Histone Deacetylase Inhibitors
McCaw, T. R., Randall, T. D., Forero, A., & Buchsbaum, D. J. (2017) · Immunotherapy · doi:10.2217/imt-2017-0134 · Cited by 48
Histone deacetylase 6 modulates macrophage infiltration during inflammation
Yan, B., Xie, S., Liu, Y., Liu, W., Li, D., Liu, M., Luo, H. R., & Zhou, J. (2018) · Theranostics · doi:10.7150/thno.25317 · Cited by 47
Curriculum vitae of HDAC6 in solid tumors
Zheng, Y., Kang, H., Wang, B., Zhu, Y.-Z., Mamun, M., Zhao, L., Nie, H., Liu, Y., Zhao, L., Zhang, X., et al. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.123219 · Cited by 43
Dong, J., Zheng, N., Wang, X., Tang, C. C., Yan, P., Zhou, H., & Huang, J. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.03.026 · Cited by 43
Moonlighting Proteins Are Important Players in Cancer Immunology
Adamo, A., Frusteri, C., Pallotta, M. T., Pirali, T., Sartoris, S., & Ugel, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.613069 · Cited by 41
Zhang, S., Bai, X., & Shan, F. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106247 · Cited by 40
Zhang, J., Ma, J., Trinh, R. T. P., Heijnen, C. J., & Kavelaars, A. (2021) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2021.12.005 · Cited by 37
Zhou, D., Choi, Y., & Kim, J. (2017) · Scientific Reports · doi:10.1038/s41598-017-08650-2 · Cited by 35
Wen, Y., Ye, S., Li, Z., Zhang, X., Liu, C., Wu, Y., Zheng, R., Xu, C., Tian, J., Shu, L., et al. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03624-y · Cited by 38
Reddy, S. R., Manjunatha, B., & Lee, S. J. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47090703 · Cited by 34
Maharaj, K. K., Powers, J. J., Mediavilla-Varela, M., Achille, A. N., Gamal, W. M., Quayle, S. N., Jones, S. S., Sahakian, E., & Pinilla-Ibarz, J. A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.590072 · Cited by 34
Self-citationHDAC6 as a potential therapeutic target for peripheral nerve disorders
Prior, R. C., Helleputte, L. V., Klingl, Y. E., & Bosch, L. V. D. (2018) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2018.1541235 · Cited by 35
Kovalovsky, D., Noonepalle, S. K. R., Suresh, M., Kumar, D., Berrigan, M. J., Gajendran, N., Upadhyay, S., Horvath, A., Kim, A., Quiceno-Torres, D., et al. (2024) · Science Advances · doi:10.1126/sciadv.adp3687 · Cited by 30
Self-citationAcetylation in Tumor Immune Evasion Regulation
Lu, J., He, X., Zhang, L., Zhang, R., & Li, W. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.771588 · Cited by 30
Targeting HDAC6 improves anti-CD47 immunotherapy
Gracia-Hernandez, M., Yende, A. S., Gajendran, N., Alahmadi, Z., Li, X., Munoz, Z., Tan, K., Noonepalle, S. K. R., Shibata, M., & Villagra, A. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-02982-4 · Cited by 29
Self-citationHDAC6-Selective Inhibitor Overcomes Bortezomib Resistance in Multiple Myeloma
Lee, S. W., Yeon, S.-K., Kim, G. W., Lee, D. H., Jeon, Y. H., Yoo, J. H., Kim, S. Y., & Kwon, S. H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22031341 · Cited by 28
Tavares, M. T., Shen, S., Knox, T. J., Hadley, M. M., Kutil, Z., Bařinka, C., Villagra, A., & Kozikowski, A. P. (2017) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.7b00223 · Cited by 28
Self-citationZhang, Q.-Q., Zhang, W.-J., & Chang, S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1168848 · Cited by 24
Cell therapy using ex vivo reprogrammed macrophages enhances antitumor immune responses in melanoma
Noonepalle, S. K. R., Gracia-Hernandez, M., Aghdam, N., Berrigan, M. J., Coulibaly, H., Li, X., Delgado, C. Z., Pletcher, A., Weselman, B., Palmer, E., et al. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03182-w · Cited by 25
Self-citationSilencing of HDAC6 as a therapeutic target in chronic lymphocytic leukemia
Maharaj, K. K., Powers, J. J., Achille, A. N., Deng, S., Fonseca, R., Pabón-Saldaña, M., Quayle, S. N., Jones, S. S., Villagra, A., Sotomayor, E. M., et al. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018020065 · Cited by 23
Self-citationRole of Histone Deacetylase 6 and Histone Deacetylase 6 Inhibition in Colorectal Cancer
Vuletić, A. M., Martinović, K. M., & Spasić, J. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics16010054 · Cited by 24
Immunological Effects of Epigenetic Modifiers
Bezu, L., Chuang, A. W., Liu, P., Kroemer, G., & Kepp, O. (2019) · Cancers · doi:10.3390/cancers11121911 · Cited by 23
Barone, S., Cassese, E., Alfano, A. I., Brindisi, M., & Summa, V. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c02067 · Cited by 22
Peng, X., Yu, Z., Surineni, G., Deng, B., Zhang, M., Li, C., Sun, Z., Pan, W., Liu, Y., Liu, S., et al. (2023) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2023.2201408 · Cited by 22
Retractedde Carvalho, L. M., Wiers, C. E., Sun, H., Wang, G., & Volkow, N. D. (2020) · Brain and Behavior · doi:10.1002/brb3.1961 · Cited by 20
Enhancing Therapeutic Approaches for Melanoma Patients Targeting Epigenetic Modifiers
Gracia-Hernandez, M., Munoz, Z., & Villagra, A. (2021) · Cancers · doi:10.3390/cancers13246180 · Cited by 22
Self-citationRadiotherapy-induced Immune Response Enhanced by Selective HDAC6 Inhibition
Noonepalle, S. K. R., Grindrod, S. C., Aghdam, N., Li, X., Gracia-Hernandez, M., Delgado, C. Z., Jung, M., Villagra, A., & Dritschilo, A. (2023) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0215 · Cited by 21
Self-citationMethylation and gene expression of histone deacetylases 6 in systemic lupus erythematosus
Fang, T., Lin, Y., Liu, C., Lin, C., Li, R., Wu, C., Ou, T., Tsai, W., & Yen, J. (2015) · International Journal of Rheumatic Diseases · doi:10.1111/1756-185x.12783 · Cited by 20
Medicinal chemistry insights into non-hydroxamate HDAC6 selective inhibitors
Faridoon, Zha, Y. L., Zhang, G., & Li, J. J. (2022) · Medicinal Chemistry Research · doi:10.1007/s00044-022-02987-8 · Cited by 19
Therapeutic options in Charcot–Marie–Tooth diseases
Mathis, S., Magy, L., & Vallat, J. (2015) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2015.1017471 · Cited by 19
Manipulation of the host protein acetylation network by human immunodeficiency virus type 1.
Jeng, M. Y., Ali, I., & Ott, M. (2015) · PubMed · doi:10.3109/10409238.2015.1061973 · Cited by 19
Khetmalis, Y. M., Fathima, A., Schweipert, M., Debarnot, C., Bandaru, N. V. M. R., Murugesan, S., Trinath, J., Meyer‐Almes, F., & Sekhar, K. V. G. C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241311044 · Cited by 19
New insights into the basic biology of acute graft-versus-host-disease
Li, A. H., Abraham, C., Wang, Y., & Zhang, Y. (2020) · Haematologica · doi:10.3324/haematol.2019.240291 · Cited by 18
Bag, A. K., Schultz, A., Bhimani, S., Stringfield, O., Dominguez, W., Mo, Q., Cen, L., & Adeegbe, D. O. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2042065 · Cited by 17
Histone acetylation modulators in breast cancer
Yuan, X., & Rosen, J. M. (2025) · Breast Cancer Research · doi:10.1186/s13058-025-02006-9 · Cited by 14
Hu, Z., Li, S., He, H., Pan, W., Liu, T., Liang, H., Xu, C., Lu, B., Tao, C., Qi, Z., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02510 · Cited by 13
Epigenetic drug development for autoimmune and inflammatory diseases
Ullah, H., & Khan, H. Z. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-816422-8.00017-9 · Cited by 13
Emerging strategies for treating autoimmune disease with genetically modified dendritic cells
Ma, Y., Shi, R., Li, F., & Chang, H. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01641-7 · Cited by 14
Brindisi, M., Barone, S., Rossi, A., Cassese, E., Gaudio, N. D., Morel, Á. J. F., Filocamo, G., Alberico, A., Fino, I. D., Gugliandolo, D., et al. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.175349 · Cited by 12
Asaad, L., Pepperrell, B., McErlean, E. M., & Furlong, F. M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26031274 · Cited by 11
Butler, R. M., McKenzie, R. C. T., Jones, C. L., Flanagan, C. E., Woollard, W. J., Demontis, M. A., Ferreira, S., Tosi, I., John, S., Whittaker, S. J., et al. (2019) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2019.03.1130 · Cited by 11
Interplay between epigenetic and genetic alterations in inborn errors of immunity
Rodríguez‐Ubreva, J., Calvillo, C. L., Satter, L. F., & Ballestar, E. (2023) · Trends in Immunology · doi:10.1016/j.it.2023.09.005 · Cited by 11
Functional Analysis of Histone Deacetylase 11 (HDAC11)
Chen, J., Sahakian, E., Powers, J. J., Lienlaf, M., Perez-Villarroel, P., Knox, T. J., & Villagra, A. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-3667-0_11 · Cited by 12
Self-citationZhang, Y., Zhang, G., Wang, Y., Ye, L., Peng, L., Shi, R., Guo, S., He, J., Yang, H., & Dai, Q. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1324859 · Cited by 10
Zwick, V., Simões‐Pires, C. A., & Cuendet, M. (2016) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2016.1180595 · Cited by 11
Expression and Function of Histone Deacetylase 10 (HDAC10) in B Cell Malignancies
Powers, J. J., Lienlaf, M., Perez-Villarroel, P., Deng, S., Knox, T. J., Villagra, A., & Sahakian, E. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-3667-0_10 · Cited by 10
Self-citationContribution of Histone Deacetylases in Prognosis and Therapeutic Management of Cholangiocarcinoma
Mastoraki, A. T., Schizas, D., Charalampakis, N., Naar, L., Ioannidi, M., Tsilimigras, D. I., Sotiropoulou, M. G., Moris, D., Vassiliu, P., & Felekouras, E. S. (2020) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-020-00454-x · Cited by 10
Wen, H., Gallo, R. A., Huang, X., Cai, J., Mei, S., Farooqı, A. A., Zhao, J., & Tao, W. (2021) · Journal of Ophthalmology · doi:10.1155/2021/5580595 · Cited by 9
Editorial: Genetic and Epigenetic Control of Immune Responses
Noonepalle, S. K. R., Karabon, L., Chiappinelli, K. B., & Villagra, A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.775101 · Cited by 9
Self-citationAdeegbe, D. O., Bag, A. K., Schultz, A., Bhimani, S., Dominguez, W., & Cen, L. (2022) · The Journal of Immunology · doi:10.4049/jimmunol.208.supp.118.11 · Cited by 7
Lower HDAC6 mRNA expression and promoter hypomethylation are associated with RA susceptibility
Fang, T., Lin, C., Lin, Y., Chiu, M., Li, R., Chan, H., Yeh, Y., & Yen, J. (2021) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2021.10.008 · Cited by 6
HDAC6: Tumor Progression and Beyond
Oliveira‐Silva, J. M., Oliveira, L. S., Tagliéri, J. V. M., Lopes, L. B., de Souza, C. V. E., Batistão, H. K. D. A., & Castro‐Gamero, A. M. (2025) · Current Cancer Drug Targets · doi:10.2174/0115680096332732241113053459 · Cited by 5
Zhao, Y., Xuan, H., Shen, C., Liu, P., Han, J. J., & Yu, W. (2022) · Phenomics · doi:10.1007/s43657-022-00045-2 · Cited by 5
Present and future perspectives for targeting histone modifications in therapy
Camilo, V., & Jerónimo, C. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-816422-8.00018-0 · Cited by 4
Peng, J., Yang, J., Antonopoulou, G., Fang, R., Adhikari, B., Vogt, M., Wolf, E., Sun, C., Du, S., Godfrey, L., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-69013-y · Cited by 4
Impact of epigenetic modifiers on the immune system
Bhat, S. A., Sureshbabu, S. K., Philip, C. S., & Chiplunkar, S. V. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-817964-2.00014-9 · Cited by 3
Kim, C. E., Lee, S.-M., Yoon, E. H., Won, H. J., Jung, Y. J., Jegal, Y., Kim, D., Kwon, B., & Seo, S. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112246 · Cited by 3
Luong, P. Q., Lee, G. B., & Kim, J. I. (2024) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2024.150800 · Cited by 1
Bag, A. K., Schultz, A., Bhimani, S., Dominguez, W., Cen, L., & Adeegbe, D. O. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.10.01.462824 · Cited by 1
DNA Methylation and Histone Modifications in Autoimmunity
Banik, D., Chiappinelli, K. B., & Villagra, A. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-809912-4.00003-9
Self-citationTogay, A., Başok, B. İ., Çolak, A., & Yılmaz, N. (2023) · Journal of Medicine and Palliative Care · doi:10.47582/jompac.1317134
WITHDRAWN: Epigenetic remodeling of the myeloid landscape of the cancer tumor microenvironment
German, B., Petkovich, D. A., & Ellis, L. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-14064-8.00002-3
Epigenetic remodeling of the myeloid landscape of the cancer tumor microenvironment
German, B., Petkovich, D. A., & Ellis, L. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-14064-8.90002-x
Additional file 1 of Targeting HDAC6 improves anti-CD47 immunotherapy
Gracia-Hernandez, M., Yende, A. S., Gajendran, N., Alahmadi, Z., Li, X., Munoz, Z., Tan, K., Noonepalle, S. K. R., Shibata, M., & Villagra, A. (2024) · Figshare · doi:10.6084/m9.figshare.25303067
Self-citation
Metadata
- Authors
- Cheng, F., Lienlaf, M., Wang, H.-W., Perez-Villarroel, P., Lee, C., Woan, K., Rock-Klotz, J., Sahakian, E., Woods, D., Pinilla-Ibarz, J., Kalin, J., Tao, J., Hancock, W., Kozikowski, A., Seto, E., Villagra, A., & Sotomayor, E. M.
- Affiliations
- Moffitt Cancer Center (US)
- Department of Immunology and Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute , Tampa, FL 33612
- Johns Hopkins University (US)
- University of Illinois Chicago (US)
- University of Pennsylvania (US)
- Corresponding author
- Cheng, Fengdong
- Lienlaf, Maritza
- Woan, Karrune
- Sahakian, Eva
- Woods, David
- Tao, Jianguo
- Villagra, Alejandro
- ORCID
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-09
- Volume
- 193
- Issue
- 6
- Pages
- 2850-2862
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- PMC
- PMC4157123
- OpenAlex
- W2151850046
- Cited by
- 106
- References
- 64
- Citations by year
- 2026: 6 · 2025: 5 · 2024: 12 · 2023: 8 · 2022: 7 · 2021: 11 · 2020: 15 · 2019: 12 · 2018: 11 · 2017: 6 · 2016: 8 · 2015: 5
- FWCI
- 2.60
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Journal of Immunology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (R21CA184612, R01CA087583, CA134807, T32CA115308, R01CA134807, R21CA153246, R01CA100850, CA87583, CA100850, P30CA076292)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Cytokine Signaling Pathways and Interactions
- Keywords
- HDAC6, STAT3, IL-10, antigen-presenting cells, dendritic cells, macrophages, T cell tolerance, STAT3 phosphorylation, epigenetic regulation, HDAC6 inhibitors, T cell activation
- MeSH terms
- Histone Deacetylase 6, Acetylation, Animals, Antigen-Presenting Cells, Cell Line, Dendritic Cells, Gene Expression Regulation, Histone Deacetylases, Immune Tolerance, Inflammation, Lymphocyte Activation, Macrophages, Male, Mice, Inbred BALB C, Mice, Inbred C57BL, Mutation, Oligopeptides, Phosphorylation, Promoter Regions, Genetic, Recombinant Proteins, Transcription, Genetic, CD4-Positive T-Lymphocytes, Gene Expression, Interleukin-10, Protein Structure, Tertiary, Mice, Knockout, RNA Interference, RNA, Small Interfering, Chromatin Immunoprecipitation, STAT3 Transcription Factor, Mice, Histone Deacetylase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
